RE:RE:RE:RE:RE:Since this BB has zero relevance, except for PUMPING IGNORE the guy Stuck-Up-The-Tree People!
The Facts Still Remain The Same:
Enrolment
- Initiated 2024 with robust site activity to start the new year:
- Enrolled patient 82 during the first week of January.
- Post-holiday break, strong screening activityresumed with more than 100 patients screened per week.
- Closing in on the interim enrollment target of 90 patients (“Interim Enrollment”); at Interim Enrollment, Baxter International (NYSE.BAX) has the option to make the second non-dilutive milestone payment to Spectral to maintain its PMX exclusive distribution rights.
- Crude mortality results at both 28-day (primary endpoint) and at one year, thus far, continue to exceed efficacy targets. (RIGHT NOW TO DATE)
Trial Sites:
- Near term onboarding of six new, high quality clinical sites.
- Expect significant site onboarding activity during the first quarter of 2024.
Up about 10% since I last Posted this at the beginning of January .....BUT SLOWLY MOVING IN THE RIGHT DIRECTION PEOPLE!
GLTA True Shareholders!
Rev